Covered recipient · General Payments record
ANNETTE C FONTAINE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$184,533.74
- Reported across 293 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $17,409.00 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,270.00 | 2 |
| Food and Beverage | $1,076.51 | 24 |
| Honoraria | $500.00 | 1 |
| Education | $74.28 | 6 |
| Travel and Lodging | $7.77 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $9,379.81 | 11 |
| Stemline Therapeutics Inc. | $5,470.35 | 5 |
| Acerta Pharma LLC | $4,184.01 | 4 |
| E.R. Squibb & Sons, L.L.C. | $1,837.71 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $1,221.00 | 1 |
| Blueprint Medicines Corporation | $1,027.61 | 2 |
| Verity Pharmaceuticals Inc. | $500.00 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $141.53 | 2 |
| Gilead Sciences, Inc. | $139.70 | 3 |
| Janssen Biotech, Inc. | $121.36 | 1 |
| ABBVIE INC. | $51.22 | 3 |
| Merck Sharp & Dohme Corporation | $43.40 | 4 |
| ASD SPECIALTY HEALTHCARE, LLC | $40.46 | 1 |
| GENZYME CORPORATION | $30.50 | 1 |
| Genmab U.S., Inc. | $26.75 | 1 |
| Celltrion USA Inc. | $24.00 | 1 |
| Astellas Pharma US Inc | $20.07 | 1 |
| Ipsen Biopharmaceuticals, Inc | $19.43 | 1 |
| Regeneron Healthcare Solutions, Inc. | $17.02 | 1 |
| BeiGene USA, Inc. | $14.36 | 1 |
| PFIZER INC. | $13.86 | 1 |
| Mirati Therapeutics, Inc. | $13.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (50)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.